Welcome to our dedicated page for FSD Pharma Class B Subordinate Voting Shares news (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma Class B Subordinate Voting Shares stock.
FSD Pharma Inc. (symbol: HUGE) is a leading biopharmaceutical company headquartered in Toronto, Canada. Originally founded in 1998, FSD Pharma is committed to developing innovative treatments for complex neuropsychiatric, neurodegenerative, and inflammatory disorders. The company operates through two main segments: Biopharmaceutical and Strategic Investments.
FSD Pharma, through its subsidiary FV Pharma Inc., focuses on producing medical-grade cannabis in Canada. The company is heavily involved in the research and development of cannabinoid-based therapies targeting central nervous system disorders, autoimmune diseases affecting the skin, gastrointestinal tract, and musculoskeletal system, such as chronic pain.
The company's core development pipeline includes FSD201, an ultra-micronized formulation of PEA, designed to treat inflammatory diseases, along with Lucid-Psych for mental health disorders and Lucid-MS for neurodegenerative conditions. FSD Pharma has formed strategic alliances with companies like SciCann Therapeutics Inc., Canntab Therapeutics, and Solarvest BioEnergy Inc. to bolster its research capabilities and expand its product portfolio.
One of the company's notable breakthroughs is the development of unbuzzd™, a proprietary blend of vitamins, minerals, and botanical extracts that aids in alcohol metabolism and mental alertness. This formulation has been licensed to Celly Nutrition Corp., which is responsible for its market launch in the United States.
FSD Pharma has been actively engaging in clinical trials to validate the efficacy and safety of its products. Recently, the company announced a Phase 1 trial for Lucid-MS aimed at evaluating its potential to prevent and reverse myelin degradation in multiple sclerosis. Another significant milestone is the METAL-2 trial, conducted in collaboration with the Applied Science and Performance Institute (ASPI), which aims to test the safety and efficacy of unbuzzd™.
FSD Pharma is also making strides in strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial properties. This diversified approach ensures a steady stream of funding for its core research and development activities.
In terms of financial health, FSD Pharma maintains a robust portfolio and is well-positioned to capitalize on future growth opportunities. The company has demonstrated a consistent commitment to advancing science and improving patient outcomes through its innovative biopharmaceutical solutions.
FSD Pharma Inc. has received a No Objection Letter from Health Canada, enabling the commencement of its Phase 1 clinical trial for LUCID-21-302 (Lucid-MS), a novel treatment for Multiple Sclerosis (MS). This trial aims to assess the safety and tolerability of Lucid-MS, a patented compound developed over 11 years, which has shown potential to prevent myelin degradation in preclinical studies. According to the MS International Foundation, the global MS therapies market is projected to grow from $22.99 billion in 2018 to $28.0 billion by 2026, highlighting the significant demand for innovative MS treatments.
FSD Pharma Inc. (NASDAQ: HUGE) is recruiting for its Phase 2 clinical trial of FSD201, aimed at treating chronic pain associated with idiopathic MCAS. The trial will enroll 60 patients at US sites, with a Canadian site to join soon. FSD201, a proprietary anti-inflammatory compound, successfully completed Phase 1 trials. The study's primary goal is a 30% reduction in pain intensity from baseline to day 28. FSD201 has also received new molecular entity (NME) designation for potential regulatory advantages. The company is focusing on providing innovative treatments for underrepresented conditions.
FSD Pharma Inc. (NASDAQ:HUGE) has submitted a Clinical Trial Application for a Phase-1 trial for LUCID-MS, a novel treatment candidate for Multiple Sclerosis (MS). LUCID-MS, a first-in-class neuroprotective compound, has demonstrated significant potential in preclinical studies by preventing myelin degradation, a key factor in MS. This compound also promotes functional recovery in experimental models. With approximately 2.2 million MS cases globally, there is a pressing need for effective treatments. FSD Pharma has two other drug candidates, enhancing its position in the biopharmaceutical sector.
FSD Pharma Inc. (NASDAQ: HUGE) has submitted a Clinical Trial Application (CTA) to initiate a Phase 1 clinical trial for Lucid-MS, an innovative drug candidate aimed at treating Multiple Sclerosis. This first-in-class neuroprotective compound has shown promising preclinical results by preventing myelin degradation and promoting recovery in experimental models. The CEO expressed optimism about Lucid-MS's potential to address unmet needs in treating progressive MS. FSD Pharma is focused on advancing its pipeline of drug candidates, including Lucid-Psych for mental health disorders and FSD201 for inflammatory diseases.
FSD Pharma Inc. (NASDAQ: HUGE) has announced a normal course issuer bid (NCIB) authorized by its Board of Directors to repurchase up to 1,925,210 Subordinate Class B Voting Shares over the next 12 months. This represents approximately 5% of the company’s outstanding shares as of January 12, 2023. The NCIB aims to utilize excess cash reserves to enhance shareholder value without disrupting ongoing ambitious growth plans. The company's Interim CEO stated that the shares are undervalued, indicating confidence in future prospects. Previous repurchases included 1,999,800 shares at approximately $1.20 CDN each.
FSD Pharma Inc. (NASDAQ: HUGE) has announced significant developments including the establishment of a new subsidiary in Australia to leverage drug development incentives. The company is enhancing its Scientific and Clinical Expert Committee with the appointments of Dr. Jeremy Chataway, Dr. Ashwin Dhanda, and Dr. Anh Lê. Furthermore, FSD Pharma is exploring new products targeting acute medical needs related to substance abuse, specifically alcohol. These initiatives aim to strengthen its pipeline and advance innovative solutions to critical health issues.
FSD Pharma Inc. (NASDAQ: HUGE) has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, California. Key executives, including Dr. Lakshmi P. Kotra and Zeeshan Saeed, will be available for meetings. FSD Pharma is focused on developing innovative pharmacological solutions, with three drug candidates in various development stages. Their subsidiaries are engaged in researching treatments for inflammatory diseases and mental health disorders, demonstrating FSD Pharma's commitment to addressing global health challenges.
FSD Pharma Inc. (NASDAQ: HUGE) announced the appointment of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. This follows the resignation of Fernando Cugliari. Dr. Kotra, an expert in medicinal chemistry with extensive research and drug development experience, has been serving as CEO of Lucid Psycheceuticals, a FSD subsidiary. Mr. Romano, a founding member of Romano Law Firm, brings a strong legal background. The company believes their expertise will significantly enhance its strategic direction.
FSD Pharma (NASDAQ: HUGE) announced the dismissal of a US$30.2 million claim by former CEO Dr. Raza Bokhari regarding wrongful dismissal. The arbitrator ruled in favor of FSD Pharma, mandating Dr. Bokhari to repay specific amounts and cover the company's arbitration costs. The current management expressed satisfaction with this outcome, viewing it as a vindication of their actions during a past proxy battle. FSD Pharma maintains a robust financial position to support its ongoing drug development initiatives, with shares trading at $1.37 on the CSE.
FSD Pharma Inc. (NASDAQ: HUGE) announced the dismissal of a $30.2 million claim by former CEO Dr. Raza Bokhari, which was ruled in favor of the company on November 9, 2022. The arbitrator not only dismissed the claim but also mandated Dr. Bokhari to repay certain amounts to FSD Pharma and cover its arbitration costs. Current leadership views this outcome as a complete vindication of their actions during the prior proxy battle, allowing them to refocus on advancing drug candidates and enhancing shareholder value.
FAQ
What is the current stock price of FSD Pharma Class B Subordinate Voting Shares (HUGE)?
What is the market cap of FSD Pharma Class B Subordinate Voting Shares (HUGE)?
What does FSD Pharma Inc. specialize in?
What are the core products of FSD Pharma?
What is unbuzzd™?
Who are the strategic partners of FSD Pharma?
Where is FSD Pharma headquartered?
What recent clinical trials has FSD Pharma announced?
What is FSD201?
How does FSD Pharma generate revenue?
What is the significance of Lucid-MS?